Our integrated genomic strategy allowed us to dissect out a core TGF-β/Smad3 gene signature that specifically reflected the tumor-suppressive activities of TGF-β in vivo and was associated with good outcome in multiple independent ER+ breast cancer cohorts. The gene discussed is ESR1; the disease is breast carcinoma.